Sugi Predict

Sugi Predict / Compounds / SCHEMBL4909989

SCHEMBL4909989

SCHEMBL4909989

COc1ccc2nc(NC(=O)Nc3cccc(F)c3)sc2c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 9/20 0.78
▸ NPC1 O15118 8/20 0.78
▸ MEN1 O00255 6/20 0.78
▸ KMT2A Q03164 6/20 0.78
▸ SMN1; SMN2 Q16637 4/20 0.78
▸ MAPT P10636 4/20 0.78
▸ POLB P06746 2/20 0.78
▸ LMNA P02545 1/20 0.78
▸ NFKB1 P19838 1/20 0.78
▸ NFKB2 Q00653 1/20 0.78
▸ RELA Q04206 1/20 0.78
▸ HDAC6 Q9UBN7 1/20 0.78
▸ HSD17B10 Q99714 2/20 0.66
▸ HTT P42858 2/20 0.64
▸ KDM4E B2RXH2 1/20 0.64
▸ ALDH1A1 P00352 1/20 0.64
▸ MCL1 Q07820 1/20 0.64
▸ SCD O00767 5/20 0.63
▸ RIPK1 Q13546 1/20 0.62
▸ RIPK3 Q9Y572 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23357 0.91 RAB9A (0.84) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL4924519 0.88 RAB9A (0.79) RAB9ANPC1MEN1KMT2ASMN1; SMN2
Frentizole SCHEMBL599582 0.88 RAB9A (1.00) RAB9ANPC1MEN1KMT2ASMN1; SMN2
Frentizole SCHEMBL11433152 0.86 RAB9A (0.98) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL8290119 0.85 DYRK1A (0.62) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL11724051 0.85 RAB9A (0.74) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL11729289 0.85 KMT2A (0.61) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL21568128 0.84 RAB9A (0.73) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL4917247 0.83 SCD (0.83) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL12199358 0.83 SCD (0.83) RAB9ANPC1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335429-A1 MOLECULAR GLUE AND SALL4 DEGRADER BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-10-10 — — US claimed
EP-4380557-A2 MOLECULAR GLUE AND SALL4 DEGRADER National University of Singapore (SG) 2024-06-12 — — EP claimed
WO-2023014296-A2 MOLECULAR GLUE AND SALL4 DEGRADER NATIONAL UNIVERSITY OF SINGAPORE (SG) 2023-02-09 — — WO claimed
US-20210380547-A1 UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-12-09 — — US claimed
WO-2020079184-A2 UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-04-23 — — WO claimed
EP-1680431-A1 BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2006-07-19 — — EP claimed
US-20050130974-A1 Benzothiazole compositions and their use as ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-06-16 — — US claimed
WO-2005037845-A1 BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-04-28 — — WO claimed
US-20240335429-A1 MOLECULAR GLUE AND SALL4 DEGRADER BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-10-10 — — US disclosed
CN-113271941-B Urea derivatives for the treatment and/or prophylaxis of cancer 法国国家科学研究中心 2024-09-20 — — CN disclosed
EP-4380557-A2 MOLECULAR GLUE AND SALL4 DEGRADER National University of Singapore (SG) 2024-06-12 — — EP disclosed
WO-2023014296-A2 MOLECULAR GLUE AND SALL4 DEGRADER NATIONAL UNIVERSITY OF SINGAPORE (SG) 2023-02-09 — — WO disclosed
US-20210380547-A1 UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-12-09 — — US disclosed
WO-2020079184-A2 UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-04-23 — — WO disclosed
US-20080039629-A1 Benzothniazole compositions and their use as ubiquition ligation inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2008-02-14 — — US disclosed
US-20080039629-A1 Benzothniazole compositions and their use as ubiquition ligation inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2008-02-14 — — US disclosed
US-20080039629-A1 Benzothniazole compositions and their use as ubiquition ligation inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2008-02-14 — — US disclosed
US-20050130974-A1 Benzothiazole compositions and their use as ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-06-16 — — US disclosed
WO-2005037845-A1 BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335429-A1 MOLECULAR GLUE AND SALL4 DEGRADER SALL4, SAV1, SUMO1 RAB9A 2386/4885NPC1 3795/4885MEN1 574/4885
US-20050130974-A1 Benzothiazole compositions and their use as ubiquitin ligase inhibitors UBQLN1, UBE2T, NEDD4 RAB9A 3792/4885NPC1 1713/4885MEN1 3866/4885
US-20210380547-A1 UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER CXCR1, CXCR2, CXCR6 RAB9A 1386/4885NPC1 331/4885MEN1 422/4885
US-20080039629-A1 Benzothniazole compositions and their use as ubiquition ligation inhibitors UBQLN1, NEDD4, UCHL5 RAB9A 3771/4885NPC1 3462/4885MEN1 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.